You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康方生物-B(9926.HK)漲超5% 多個項目取得進展有望迎來快速成長
格隆匯 07-09 15:31
格隆匯7月9日丨康方生物-B(9926.HK)反彈逾5%,報57.4港元,總市值469億港元。近期公司AK104(PD-1/CTLA-4雙抗)多個聯合療法陸續取得進展,興業證券指出,整體來看,公司在雙抗領域持續取得進展,隨着後續這些項目的不斷落地,公司在雙抗領域的領頭羊地位將進一步得到鞏固。伴隨產品獲批適應症的增加、差異化的雙抗產品陸續兑現以及強大的執行力,公司有望迎來快速成長。大和提到,康方的在研產品AK104料將於今年第三季在中國提交新藥註冊申請,並將在年內就AK104啟動兩項臨牀三期試驗,將其評級由“跑贏大市”升至“買入”,目標價維持69.9港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account